Tuberous sclerosis complex (TSC) is an autosomal dominant disease characterised by abnormal cell proliferation and differentiation that affects multiple organs and can lead to the growth of hamartomas. Tuberous sclerosis complex is caused by the disinhibition of the protein mTOR (mammalian target of rapamycin). In the past, various therapeutic approaches, even if only symptomatic, have been attempted to improve the clinical effects of this disease. While all of these therapeutic strategies are useful and are still used and indicated, they are symptomatic therapies based on the individual symptoms of the disease and therefore not fully effective in modifying long-term outcomes. A new therapeutic approach is the introduction of allosteric inhibitors of mTORC1, which allow restoration of metabolic homeostasis in mutant cells, potentially eliminating most of the clinical manifestations associated with Tuberous sclerosis complex. Everolimus, a mammalian target of the rapamycin inhibitor, is able to reduce hamartomas, correcting the specific molecular defect that causes Tuberous sclerosis complex. In this review, we report the findings from the literature on the use of everolimus as an effective and safe drug in the treatment of TSC manifestations affecting various organs, from the central nervous system to the heart.

Paradigm shift in the treatment of tuberous sclerosis: Effectiveness of everolimus / R. Previtali, G. Prontera, E. Alfei, L. Nespoli, S. Masnada, P. Veggiotti, S. Mannarino. - In: PHARMACOLOGICAL RESEARCH. - ISSN 1043-6618. - 195:(2023 Sep), pp. 106884.1-106884.12. [10.1016/j.phrs.2023.106884]

Paradigm shift in the treatment of tuberous sclerosis: Effectiveness of everolimus

R. Previtali
Primo
;
P. Veggiotti
Penultimo
;
2023

Abstract

Tuberous sclerosis complex (TSC) is an autosomal dominant disease characterised by abnormal cell proliferation and differentiation that affects multiple organs and can lead to the growth of hamartomas. Tuberous sclerosis complex is caused by the disinhibition of the protein mTOR (mammalian target of rapamycin). In the past, various therapeutic approaches, even if only symptomatic, have been attempted to improve the clinical effects of this disease. While all of these therapeutic strategies are useful and are still used and indicated, they are symptomatic therapies based on the individual symptoms of the disease and therefore not fully effective in modifying long-term outcomes. A new therapeutic approach is the introduction of allosteric inhibitors of mTORC1, which allow restoration of metabolic homeostasis in mutant cells, potentially eliminating most of the clinical manifestations associated with Tuberous sclerosis complex. Everolimus, a mammalian target of the rapamycin inhibitor, is able to reduce hamartomas, correcting the specific molecular defect that causes Tuberous sclerosis complex. In this review, we report the findings from the literature on the use of everolimus as an effective and safe drug in the treatment of TSC manifestations affecting various organs, from the central nervous system to the heart.
Angiomyolipoma; Astrocytomas; Cardiac rhabdomyomas; Everolimus; MTOR inibitors; Tuberous sclerosis complex
Settore MED/39 - Neuropsichiatria Infantile
set-2023
Article (author)
File in questo prodotto:
File Dimensione Formato  
2023_Previtali_Paradigm shift in the treatment of TSC effectiveness of everolimus.pdf

accesso aperto

Descrizione: Article
Tipologia: Publisher's version/PDF
Dimensione 924.83 kB
Formato Adobe PDF
924.83 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1085392
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 6
social impact